| News
Jura has plenty of greenfield sites
14.11.2019
The canton of Jura has more than 544 hectares of building land available, a study from the Federal Institute of Technology in Zurich (ETH) has found. Local authorities have now been presented with a detailed inventory.
Le Noirmont. (Img: République et Canton du Jura/Jura Tourisme)
The canton of Jura boasts generous building land. Now, a new study from the ETH has shown exactly how much space is available for building and where it is. The findings are based on the Raum+ method, which has previously been used to examine building land in Eastern and Central Switzerland. According to the study, the canton of Jura has an available total of 544 hectares across 2,782 sites. This equates to 15 per cent of the overall building zones in the canton, according to a cantonal statement.
Around half of the sites are in the Porrentruy district, a region that represents around a third of the inhabitants and employees. 45 per cent are inside overbuilt areas. Of the sites, 67 are bigger than one hectare. Together, these make up 26 per cent of the reserves. Another 26 per cent are available immediately, while 25 per cent are in industrial estates.
An inventory has been provided to the local authorities to help with spatial development.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Ricola earns the trust of Switzerland
Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.
Read More
docdok.health involved in coronavirus research project
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
Celonic agrees cooperation to combat coronavirus
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
Idorsia receives payment of 45 million US dollars
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard robot disinfects using UV light
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche authorized to distribute coronavirus antibody tests
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Read More
Healthtech sector growing rapidly in the Basel Area
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.
Read More
Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
Read More
University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Read More
